Table 6. Promoter hypermethylation in NSCLC tissues – multivariable models assessing histologic type, tumor size, and gender. (^# OR and 95% CI).

	Squamous vs. Adeno*	Tumor Size (per cm)	Female vs. Male
APC	0.2 (0.0-0.6)	1.2 (0.7-2.1)	0.7 (0.1-4.4)
BVES	0.8 (0.1-4.3)	1.3 (0.8-2.2)	1.8 (0.2-13.0)
CCND2	0.0 (0.0-0.4)	1.0 (0.6-1.7)	1.6 (0.2-14.3)
CDH1**	0.6 (0.0-α)	1.1 (0.4-3.0)	0.4 (0.0-α)
CDH13	1.0 (0.0-37.8)	1.5 (0.7-2.9)	3.5 (0.5-24.6)
CDKN2A	5.8 (1.6-20.7)	1.3 (0.8-2.2)	0.9 (0.0-20.0)
DAPK1**	3.6 (0.2-71.6)	1.0 (0.3-2.7)	1.5 (0.0-α)
KCNH5**	0.1 (0.0-0.5)	1.4 (0.8-2.6)	4.9 (1.1-22.1)
KCNH8**	0.3 (0.0-5.0)	1.3 (0.3-6.1)	33.4 (3.3-340)
MGMT**	7.3 (0.4-121)	1.1 (0.4-2.9)	1.8 (0.0-α)
OPCML**	0.1 (0.0-1.5)	1.3 (0.7-2.6)	3.1 (0.3-30.9)
RARB	1.2 (0.3-5.2)	1.1 (0.6-1.8)	3.2 (1.0-9.7)
RASSF1	0.5 (0.1-2.2)	0.9 (0.5-1.6)	1.1 (0.0-82.3)
RUNX	0.1 (0.0-0.7)	1.1 (0.6-2.3)	1.3 (0.0-96.8)
TMS1**	0.3 (0.0-8.9)	1.3 (0.5-3.4)	0.8 (0.0-α)

^#OR – Odds ratio with 95% confidence interval, adjusted for multiple comparisons

^*Adenocarcinoma includes BAC and Non-BAC

^**Exact Logistic Regression

^***MGMT never methylated in Adenocarcinoma